Literature DB >> 16730351

Cytokines produced by cultured human umbilical cord blood (HUCB) cells: implications for brain repair.

Mary B Newman1, Alison E Willing, John J Manresa, Cyndy Davis Sanberg, Paul R Sanberg.   

Abstract

The potential therapeutic benefits from human umbilical cord blood (HUCB) cells for the treatment of injuries, diseases, and neurodegeneration are becoming increasingly recognized. The transplantation or infusion of cord blood cells in various animal models, such as ischemia/stroke, traumatic brain injury, myocardial infarction, Parkinson's disease, and amyotropic lateral sclerosis, has resulted in amelioration of behavioral deficits, and with some diseases, a prolonged lifespan decreased neuropathology. Previously, we reported the migration of HUCB cells to ischemic brain supernatant (tissue extracts) is time-dependent, and the expression of specific chemokines responds to this migration pattern. The mechanism(s) responsible for these effects are unknown. The expression of cytokines and chemokines produced by HUCB cells (under various culturing conditions) was investigated in this study. IL-8, MCP-1, and IL-1alpha were consistently expressed by the HUCB mononuclear cells regardless of the culture condition. These results provide insights to factors that may be partially responsible for the functional improvements seen in the animal models of injury investigating the therapeutic use of HUCB cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730351     DOI: 10.1016/j.expneurol.2006.04.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  32 in total

1.  Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.

Authors:  Ike dela Peña; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2015-12       Impact factor: 6.829

2.  Human umbilical cord blood cells directly suppress ischemic oligodendrocyte cell death.

Authors:  A A Hall; A G Guyer; C C Leonardo; C T Ajmo; L A Collier; A E Willing; K R Pennypacker
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

3.  Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Authors:  William V Nikolic; Huayan Hou; Terrence Town; Yuyan Zhu; Brian Giunta; Cyndy D Sanberg; Jin Zeng; Deyan Luo; Jared Ehrhart; Takashi Mori; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

4.  Implication of cord blood for cell-based therapy in refractory childhood diseases.

Authors:  Young-Ho Lee
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

5.  Human Umbilical Cord Blood Cells Have Trophic Effects on Young and Aging Hippocampal Neurons in Vitro.

Authors:  Ning Chen; Jennifer Newcomb; Svitlana Garbuzova-Davis; Cyndy Davis Sanberg; Paul R Sanberg; Alison E Willing
Journal:  Aging Dis       Date:  2010-12-01       Impact factor: 6.745

Review 6.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

7.  Stem cells decreased neuronal cell death after hypoxic stress in primary fetal rat neurons in vitro.

Authors:  Tetsuro Sakai; Yan Xu
Journal:  Cell Transplant       Date:  2011-06-07       Impact factor: 4.064

8.  Human umbilical cord blood cells protect oligodendrocytes from brain ischemia through Akt signal transduction.

Authors:  Derrick D Rowe; Christopher C Leonardo; Jesus A Recio; Lisa A Collier; Alison E Willing; Keith R Pennypacker
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

Review 9.  Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options.

Authors:  Courtney A McDonald; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 10.  Cord blood stem cells: a review of potential neurological applications.

Authors:  David T Harris
Journal:  Stem Cell Rev       Date:  2008-08-05       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.